Thalidomide News and Research

RSS

Thalidomide is a drug that is used to treat multiple myeloma in patients who have just been diagnosed, and a painful skin disease related to leprosy. It is also being studied in the treatment of other types of cancer. Thalidomide belongs to the family of drugs called angiogenesis inhibitors. Also called Thalomid.

Limited PBS coverage widens pregnancy nausea treatment disparities in Australia

Pregnant women in Australia are facing an unfair two-tiered system for managing morning sickness, with financial status impacting who can access the full range of modern anti-nausea medications available, rather than simply clinical need.

5 Aug 2026

Can ibuprofen improve drug-resistant tuberculosis treatment?

While ibuprofen reduced inflammatory markers in drug-resistant TB patients, it did not enhance treatment outcomes, indicating the need for further research.

3 Jul 2026

Copper-based nanoplatform shows promise against metastatic tumor growth

What happens if cancer cells lose both their mitochondrial energy supply and their glycolytic backup system? This question is central to a new study published in Research by researchers from Northwestern Polytechnical University and collaborating institutions.

10 May 2026

Personalized model offers better blood pressure estimates from ankle measurements

A new method improving the accuracy of interpreting blood pressure measurements taken at the ankle could be crucial for people who cannot have their arm blood pressure measured.

12 Jun 2025

Metronomic chemotherapy offers hope for children with neuroblastoma

Neuroblastoma is the most common extracranial solid tumor in children, with nearly 50% of cases diagnosed at an advanced stage, often with metastatic disease.

23 Jan 2025

New push for stricter chemical laws to shield kids from harmful exposure

Research highlights the rising impact of synthetic chemicals on children's health, linking them to noncommunicable diseases and advocating for stringent global regulations.

13 Jan 2025

Scientists fear what’s next for public health if RFK Jr. is allowed to ‘go wild’

Many scientists at the federal health agencies await the second Donald Trump administration with dread as well as uncertainty over how the president-elect will reconcile starkly different philosophies among the leaders of his team.

14 Nov 2024

Cancer drug shows promise for treating rare bleeding disorder

A clinical trial has demonstrated that the cancer drug pomalidomide is safe and effective in treating hereditary hemorrhagic telangiectasia (HHT), a rare bleeding disorder that impacts more than 1 in 5,000 people worldwide. The trial, led by Keith McCrae, M.D., of Cleveland Clinic and supported by the National Institutes of Health, was stopped early because of these successful findings, and has been published in the New England Journal of Medicine.

19 Sep 2024

New heart organoid model could revolutionize drug development and toxicology studies

Heart disease kills 18 million people each year, but the development of new therapies faces a bottleneck: no physiological model of the entire human heart exists – so far.

28 Nov 2023

Stanford chemists uncover new pathway for protein degradation, opening door to new therapeutics

When targeting problem proteins involved in causing or spreading disease, a drug will often clog up a protein's active site so it can't function and wreak havoc.

25 Oct 2023

In utero exposure to anti-nausea drug shown to increase risk of adult-onset colorectal cancer

Prenatal exposure to an anti-nausea drug commonly used in the 1960s and 1970s has been shown to increase risk of colorectal cancer in adult offspring, according to a study by researchers at UTHealth Houston.

10 Mar 2023

The prevalence of spike-protein antibodies following at least 3 COVID-19 vaccine doses in immunocompromised individuals

Researchers determined the prevalence of antibodies against the SARS-CoV-2 spike glycoprotein following three or more doses of COVID-19 vaccines among immunocompromised individuals.

17 Feb 2023

Exploring molecular docking and molecular dynamics simulations as advanced tools for novel antiviral drug discovery

Researchers presented an overview of factors influencing emerging infectious diseases. They also highlighted the importance of molecular dynamic (MD) simulations and molecular docking (MDO) analysis for combating these diseases.

17 Oct 2022

Study identifies critical genes and biological pathways related to COVID-19 myocarditis

Scientists from China have recently deciphered the genetic network and biological mechanisms associated with COVID-19 myocarditis using bioinformatic methods.

28 Jun 2022

Study reveals the benefits of using thalidomide in patients with severe arteriovenous malformations

The same properties that caused birth defects when it was given to pregnant women, the inhibition of blood vessel formation (anti-angiogenesis), have led to an interest in thalidomide's therapeutic utility in other fields.

10 Jun 2022

Addition of left-handed chiral gold nanoparticles can enhance vaccine efficacy by more than 25%

Vaccines can be made over 25% more effective by adding left-handed chiral gold nanoparticles as adjuvants, according to a study by an international collaboration in which Brazilian researchers took part. An article reporting the results is published in Nature.

18 Apr 2022

Improving our understanding of a severe pregnancy sickness (Hyperemesis Gravidarum)

News-Medical talks to Dr. Marlena Fejzo about a breakthrough in the understanding of hyperemesis gravidarum, and how it could improve maternal health around the world.

5 Apr 2022

New analysis method to identify interacting proteins in a protein degrader-dependent manner

Protein degraders, which induce the protein degradation of target proteins, are expected to be the "next-generation drugs" because they can remove disease-related proteins from cells.

8 Mar 2022

$Clinical trial shows preliminary efficacy of all-oral regimen for patients with lenalidomide-refractory multiple myeloma$

Clinical trial shows preliminary efficacy of all-oral regimen for patients with lenalidomide-refractory multiple myeloma

Early results from an Alliance for Clinical Trials in Oncology randomized clinical trial of adults with multiple myeloma relapsing on frontline lenalidomide therapy showed that adding ixazomib (Ninlaro®) to pomalidomide and dexamethasone as part of second line therapy extended the length of time patients lived before their disease worsened (progression-free survival) compared with patients who received pomalidomide and dexamethasone.

21 Dec 2021

Benjamin L. Ebert receives Sjöberg Prize for breakthrough research on blood cancer

Benjamin L. Ebert, USA, receives this year's Sjöberg Prize, worth one million US dollars, for his research into how lenalidomide works as a treatment for blood cancer.

15 Feb 2021